Literature DB >> 23187457

Gaps in monitoring during oral anticoagulation: insights into care transitions, monitoring barriers, and medication nonadherence.

Adam J Rose1, Donald R Miller2, Al Ozonoff3, Dan R Berlowitz4, Arlene S Ash5, Shibei Zhao6, Joel I Reisman6, Elaine M Hylek7.   

Abstract

BACKGROUND: Among patients receiving oral anticoagulation, a gap of > 56 days between international normalized ratio tests suggests loss to follow-up that could lead to poor anticoagulation control and serious adverse events.
METHODS: We studied long-term oral anticoagulation care for 56,490 patients aged 65 years and older at 100 sites of care in the Veterans Health Administration. We used the rate of gaps in monitoring per patient-year to predict percentage time in therapeutic range (TTR) at the 100 sites.
RESULTS: Many patients (45%) had at least one gap in monitoring during an average of 1.6 years of observation; 5% had two or more gaps per year. The median gap duration was 74 days (interquartile range, 62-107). The average TTR for patients with two or more gaps per year was 10 percentage points lower than for patients without gaps (P < .001). Patient-level predictors of gaps included nonwhite race, area poverty, greater distance from care, dementia, and major depression. Site-level gaps per patient-year varied from 0.19 to 1.78; each one-unit increase was associated with a 9.2 percentage point decrease in site-level TTR (P < .001).
CONCLUSIONS: Site-level gap rates varied widely within an integrated care system. Sites with more gaps per patient-year had worse anticoagulation control. Strategies to address and reduce gaps in monitoring may improve anticoagulation control.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23187457      PMCID: PMC5991554          DOI: 10.1378/chest.12-1119

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  17 in total

1.  Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA).

Authors:  Adam J Rose; Elaine M Hylek; Al Ozonoff; Arlene S Ash; Joel I Reisman; Dan R Berlowitz
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-11-23

2.  Organizational characteristics of high- and low-performing anticoagulation clinics in the Veterans Health Administration.

Authors:  Adam J Rose; Beth Ann Petrakis; Patricia Callahan; Scott Mambourg; Dimple Patel; Elaine M Hylek; Barbara G Bokhour
Journal:  Health Serv Res       Date:  2012-02-02       Impact factor: 3.402

Review 3.  Measuring quality of oral anticoagulation care: extending quality measurement to a new field.

Authors:  Adam J Rose; Dan R Berlowitz; Susan M Frayne; Elaine M Hylek
Journal:  Jt Comm J Qual Patient Saf       Date:  2009-03

4.  Studying outcomes and hospital utilization in the elderly. The advantages of a merged data base for Medicare and Veterans Affairs hospitals.

Authors:  C Fleming; E S Fisher; C H Chang; T A Bubolz; D J Malenka
Journal:  Med Care       Date:  1992-05       Impact factor: 2.983

5.  Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA).

Authors:  A J Rose; E M Hylek; A Ozonoff; A S Ash; J I Reisman; D R Berlowitz
Journal:  J Thromb Haemost       Date:  2010-10       Impact factor: 5.824

6.  Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.

Authors:  Stuart J Connolly; Janice Pogue; John Eikelboom; Gregory Flaker; Patrick Commerford; Maria Grazia Franzosi; Jeffrey S Healey; Salim Yusuf
Journal:  Circulation       Date:  2008-10-27       Impact factor: 29.690

7.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Jack Ansell; Jack Hirsh; Elaine Hylek; Alan Jacobson; Mark Crowther; Gualtiero Palareti
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

8.  A method to determine the optimal intensity of oral anticoagulant therapy.

Authors:  F R Rosendaal; S C Cannegieter; F J van der Meer; E Briët
Journal:  Thromb Haemost       Date:  1993-03-01       Impact factor: 5.249

9.  Prediction of hemorrhagic and thrombotic events in patients with mechanical heart valve prostheses treated with oral anticoagulants.

Authors:  Y van Leeuwen; F R Rosendaal; S C Cannegieter
Journal:  J Thromb Haemost       Date:  2007-12-13       Impact factor: 5.824

10.  Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?

Authors:  Alan S Go; Elaine M Hylek; Yuchiao Chang; Kathleen A Phillips; Lori E Henault; Angela M Capra; Nancy G Jensvold; Joe V Selby; Daniel E Singer
Journal:  JAMA       Date:  2003-11-26       Impact factor: 56.272

View more
  17 in total

Review 1.  A Practical Guide to Using the Positive Deviance Method in Health Services Research.

Authors:  Adam J Rose; Megan B McCullough
Journal:  Health Serv Res       Date:  2016-06-28       Impact factor: 3.402

2.  Atrial fibrillation and prestroke cognitive impairment in stroke.

Authors:  Solveig Horstmann; Timolaos Rizos; Geraldine Rauch; Maximilian Fuchs; Cathrin Arden; Roland Veltkamp
Journal:  J Neurol       Date:  2014-01-12       Impact factor: 4.849

3.  Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease.

Authors:  Felix Yang; Jessica A Hellyer; Claire Than; Aditya J Ullal; Daniel W Kaiser; Paul A Heidenreich; Donald D Hoang; Wolfgang C Winkelmayer; Susan Schmitt; Susan M Frayne; Ciaran S Phibbs; Mintu P Turakhia
Journal:  Heart       Date:  2016-11-15       Impact factor: 5.994

4.  Potential Causes and Implications of Low Target Therapeutic Ratio in Warfarin-Treated Patients for Thrombosis Prophylaxis: A Single-Center Experience.

Authors:  Halil Atas; Ahmet Anıl Sahin; Dilek Barutçu Atas; Murat Sunbul; Alper Kepez; Mehmet Agirbasli
Journal:  Clin Appl Thromb Hemost       Date:  2017-03-01       Impact factor: 2.389

5.  Warfarin Monitoring in Safety-Net Health Systems: Analysis by Race/Ethnicity and Language Preference.

Authors:  Anjana E Sharma; Elaine C Khoong; Natalie Rivadeneira; Maribel Sierra; Margaret C Fang; Neha Gupta; Rajiv Pramanik; Helen Tran; Tyler Whitezell; Valy Fontil; Shin-Yu Lee; Urmimala Sarkar
Journal:  J Gen Intern Med       Date:  2022-01-06       Impact factor: 6.473

Review 6.  Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement.

Authors:  Elaine M Hylek
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

7.  Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.

Authors:  Supriya Shore; Evan P Carey; Mintu P Turakhia; Cynthia A Jackevicius; Fran Cunningham; Louise Pilote; Steven M Bradley; Thomas M Maddox; Gary K Grunwald; Anna E Barón; John S Rumsfeld; Paul D Varosy; Preston M Schneider; Lucas N Marzec; P Michael Ho
Journal:  Am Heart J       Date:  2014-04-05       Impact factor: 4.749

8.  Time in therapeutic range: Warfarin anticoagulation for atrial fibrillation in a community-based practice.

Authors:  Derek Gateman; Melissa Elizabeth Trojnar; Gina Agarwal
Journal:  Can Fam Physician       Date:  2017-10       Impact factor: 3.275

9.  Depressive symptoms as a novel risk factor for recurrent venous thromboembolism: a longitudinal observational study in patients referred for thrombophilia investigation.

Authors:  Roland von Känel; Angelina Margani; Stefanie Stauber; Fiorenza A Meyer; Franziska Demarmels Biasiutti; Franziska Vökt; Thomas Wissmann; Bernhard Lämmle; Paul S Lukas
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

10.  The adherence to initial processes of care in elderly patients with acute venous thromboembolism.

Authors:  Anna K Stuck; Marie Méan; Andreas Limacher; Marc Righini; Kurt Jaeger; Hans-Jürg Beer; Joseph Osterwalder; Beat Frauchiger; Christian M Matter; Nils Kucher; Michael Egloff; Markus Aschwanden; Marc Husmann; Anne Angelillo-Scherrer; Nicolas Rodondi; Drahomir Aujesky
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.